Intrance Medical Systems Inc, a subsidiary of Sweden-based Intrance Holdings AB, has secured financing from Swedish real estate investor Erik Selin through his private company, Erik Selin Fastigheter AB. Erik

Bioneer has announced a strategic collaboration with the National Biologics Facility (NBF) to commercialize their combined CRO services for mammalian expression of recombinant proteins. The entity, previously named CHO CORE,

Calliditas Therapeutics has announced that the U.S. Food and Drug Administration has extended the PDUFA goal date for its New Drug Application (NDA) seeking accelerated approval for Nefecon to December

Sprint Bioscience is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs

Diamyd Medical has successfully completed a directed share issue of 5 357 143 B-shares at a price of SEK  28 per share. Through the Directed Share Issue, the company will

The company has received approval to be able to give additional doses of ACD856 in their clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability

Cereno Scientific has announced that a collaboration agreement has been entered with Abbott regarding use of its CardioMEMS HF System in the upcoming Phase II study with Cereno’s drug candidate

Almi Invest will invest just over 2 million SEK in the newly founded Uppsala-based company Strike Pharma. As previously reported by NLS, an immunotherapeutic cancer vaccine delivery-platform has been developed

The purpose of the share issue is to fund an enhanced clinical trial program that can shorten the development time and increase the commercial potential of the company’s drug candidate

The two companies have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space. The aim with the agreement is to solve the challenge of

Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This marks the

Hansa Biopharma has announced that its treatment Idefirix is, as of August 1, reimbursable and available for use in the Netherlands. Idefirix is the first and only treatment approved for

The patent forms the basis of a new vaccine platform that the company has developed in parallel with existing platforms. The company has received a Notice of Allowance of its

Anocca has announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the company’s industrialised cellular biology platform and progress its pipeline of

Ipsen and IRLAB have signed a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist. “We are excited to enter this licensing